What are you looking for?

Library
Clinical Study

Effect of switching from cigarette smoking to Platform 1 on exercise capacity

Full Title

A randomized, controlled, open-label, 4-arm parallel group study to evaluate the effect of switching from cigarette smoking to the use of Platform 1 in healthy adult current smokers on exercise capacity and trainability


Authored by  PMI
Abstract

This study is part of the global clinical assessment program of Platform 1. It is designed to provide scientific evidence to further substantiate the reduced risk potential of using a heated tobacco product (Platform 1) as compared to smoking cigarettes. The main goals of this exploratory study are to assess whether switching from cigarette smoking to using Platform 1 will influence: 1) maximum oxygen uptake during incremental exercise (VO2max) and exercise capacity, 2) ability to perform exercise training and thereby influence, 3) VO2max after 12 weeks of exercise training, 4) physiological parameters and biological health markers, and finally 5) physical activity levels in daily life.

Summary

Recruitment  Active, not recruiting
Study Results No Results Available
Enrollment  90
Study Type  Interventional
Other IDs P1-EXC-01-EU








Our RRPs

Reduced-risk products ("RRPs") is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking. We have a range of RRPs in various stages of development, scientific assessment and commercialization. Because our RRPs do not burn tobacco, they produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.